Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525173 · ClinicalTrials.gov registry record · Phase 4
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT01525173 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 137 participants.
The verdict
NCT01525173, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Interventions
- DRUG 0.1% brimonidine tartrate ophthalmic solution
- DRUG 0.01% bimatoprost ophthalmic solution
- DRUG 0.2% hypromellose lubricant eye drops
- DRUG latanoprost 0.005% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525173
The ClinicalTrials.gov registry entry for NCT01525173 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 0.1% brimonidine tartrate ophthalmic solution is the first listed.
NCT01525173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525173 about?
NCT01525173 is a clinical study titled "A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension". This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ...
What is the current status of trial NCT01525173?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2012-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01525173?
The interventions under investigation include: 0.1% brimonidine tartrate ophthalmic solution (DRUG), 0.01% bimatoprost ophthalmic solution (DRUG), 0.2% hypromellose lubricant eye drops (DRUG), latanoprost 0.005% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01525173?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.